Status:
COMPLETED
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma Korea, Inc.
Conditions:
Overactive Bladder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.
Eligibility Criteria
Inclusion
- Symptoms of overactive bladder
- Must be able to complete the micturition diary
Exclusion
- Pregnant or lactating
- Clinically significant outflow obstruction
- Significant post void residual urine
- Significant stress incontinence
- Urinary tract infection
- Chronic inflammation
- Bladder stones
- Previous pelvic radiation therapy
- Previous or current malignant disease of the pelvic organs
- Uncontrolled narrow angle glaucoma
- Urinary or gastric retention
- Electrostimulation therapy
- Bladder training
- Diabetic neuropathy
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00189800
Last Update
November 17 2011
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Anyang, South Korea
2
Bucheon-si, South Korea
3
Busan, South Korea
4
Cheonan, South Korea